Systemic Lupus Erythematosus — Written Clinical Reasoning

SAQ 1 — Integrated Management of Proliferative Class IV Lupus Nephritis (20 marks, 30 minutes)

Prompt: Outline your integrated management plan for this patient with active class IV (A/C) proliferative lupus nephritis, including: (a) the immediate supportive and blood pressure measures; (b) the induction regimen with exact drugs, doses, route, frequency and duration, citing the pivotal trials; (c) the principles of glucocorticoid use and the target at 6 months; (d) the planned maintenance therapy and its duration; (e) the role of novel agents (voclosporin, belimumab); and (f) the considerations for her future fertility and pregnancy planning given the immunosuppressive regimen. [1]

Model Answer

(a) Immediate supportive and blood pressure measures (3 marks): [1]

This patient has active proliferative class IV lupus nephritis with nephritic and nephritic-nephrotic overlap features (proteinuria, active sediment, hypertension, rising creatinine). My immediate measures are:

• Blood pressure control with an ACE inhibitor or angiotensin receptor blocker (for example, ramipril 2.5 to 10 mg daily or losartan 50 to 100 mg daily). RAAS blockade reduces intraglomerular pressure, reduces proteinuria, and slows progression; the target blood pressure is below 130/80. I would monitor potassium and creatinine closely on initiation.
• Continue hydroxychloroquine 400 mg daily (5 mg/kg/day). It is indicated for every patient with SLE and reduces lupus nephritis recurrence, with a survival benefit demonstrated in the LUMINA cohort [2].
• Baseline investigations before immunosuppression: full blood count, renal and liver function, hepatitis B and C serology, HIV, quantiferon or tuberculin skin test, fasting glucose and lipids, and a pregnancy test (beta-hCG).
• Venous thromboembolism prophylaxis if admitted and immobilised, given the nephrotic-range proteinuria and hypercoagulable state.
• Vaccination status review before immunosuppression (pneumococcal, influenza, hepatitis B, COVID-19; avoid live vaccines during immunosuppression).

(b) Induction regimen (5 marks): [1]

The 2019 EULAR/ERA-EDTA recommendations [5] and KDIGO 2021 guideline define the standard induction for class III or IV lupus nephritis as glucocorticoids plus either mycophenolate mofetil or low-dose intravenous cyclophosphamide. My choice is:

Glucocorticoids: Methylprednisolone 500 to 1000 mg intravenously daily for 3 days, followed by oral prednisone 0.3 to 0.5 mg/kg/day (the modern EULAR-preferred lower starting dose, approximately 25 to 30 mg daily), tapering to below 5 to 7.5 mg by 6 months. [1]

Plus mycophenolate mofetil — my preferred first-line agent. Target dose 2 to 3 g/day (start 500 mg twice daily, titrate up over 2 to 4 weeks to minimise gastrointestinal intolerance). The ALMS trial (Appel et al, 2009) demonstrated that mycophenolate was non-inferior (not superior) to high-dose intravenous cyclophosphamide for induction, with response rates of 56.2 per cent versus 53.0 per cent [3]. Mycophenolate is preferred in this patient because she wishes to conceive in the future — cyclophosphamide is gonadotoxic and would threaten her fertility.

The alternative — low-dose cyclophosphamide (Euro-Lupus regimen): 500 mg intravenously every 2 weeks for 6 doses (cumulative 3 g). The Euro-Lupus Nephritis Trial (Houssiau et al, 2002) established this as equivalent in efficacy to high-dose NIH cyclophosphamide but with fewer severe infections [4]. I would prefer cyclophosphamide if she had severe crescentic disease with a rapidly rising creatinine or if she were of African or Hispanic ancestry (a subgroup in ALMS favouring mycophenolate, but with severe disease cyclophosphamide remains a strong option). Given her crescents (25 per cent) I would discuss the Euro-Lupus regimen as an alternative, but mycophenolate is the better choice for fertility preservation.

(c) Glucocorticoid principles and target (3 marks): [1]

The aim is the lowest effective glucocorticoid dose for the shortest duration, because cumulative steroid exposure contributes substantially to damage (osteoporosis, avascular necrosis, diabetes, hypertension, cataracts, infection). The EULAR recommendation is a starting prednisone dose of 0.3 to 0.5 mg/kg/day after pulse therapy, tapering to below 5 to 7.5 mg by 6 months. The target at 6 months is a renal response — defined as a reduction in proteinuria (urine PCR below 500 to 700 mg/mmol) with stabilised renal function. I would give bone protection (calcium, vitamin D, and a bisphosphonate if indicated), pneumocystis prophylaxis (trimethoprim-sulfamethoxazole) while on moderate-dose steroids and mycophenolate, and gastric protection if needed. [1]

(d) Maintenance therapy and duration (3 marks): [1]

After a 3 to 6 month induction, maintenance with mycophenolate mofetil (or azathioprine 2 mg/kg/day if pregnancy is planned) plus low-dose or no glucocorticoid. The ALMS maintenance trial (Dooley et al, 2011) showed mycophenolate was superior to azathioprine for preventing treatment failure and renal flare. Maintenance is continued for years — at least 3 to 5 years after complete remission — because premature cessation carries a high relapse rate (30 to 50 per cent), and each flare contributes to chronic irreversible damage captured by the chronicity index. Hydroxychloroquine is continued indefinitely because it reduces renal flare risk. [1]

(e) Role of novel agents (3 marks): [1]

• Voclosporin — a novel calcineurin inhibitor. The AURORA trial (Rovin et al, 2021) showed that adding voclosporin to mycophenolate and rapidly tapered low-dose steroids increased complete renal response at 52 weeks to 41 per cent versus 23 per cent with placebo, with an early separation by 4 weeks. It would be a rational add-on for this patient with active crescentic class IV disease, especially given the need for rapid response and steroid-sparing.
• Belimumab — anti-BAFF/BLyS. Approved for SLE and now with a renal indication; useful as an add-on for refractory nephritis and to reduce steroid exposure.
• Rituximab is NOT first-line — the LUNAR trial did not meet its primary endpoint when added to mycophenolate and steroids. It has a role in refractory disease or where mycophenolate and cyclophosphamide are contraindicated. [1]

(f) Fertility and pregnancy planning (3 marks): [1]

This is a critical consideration because she wishes to conceive. Mycophenolate is teratogenic and must be stopped at least 3 months before conception, switching to azathioprine (safe in pregnancy). Cyclophosphamide is gonadotoxic and would threaten her future fertility, which is another reason to favour mycophenolate for induction; if cyclophosphamide were unavoidable, I would consider GnRH agonist ovarian protection. She must achieve at least 6 months of renal quiescence (inactive sediment, stable creatinine, proteinuria controlled) before conception. Hydroxychloroquine is continued throughout pregnancy. I would screen for antiphospholipid and anti-Ro/anti-La antibodies now, to stratify future pregnancy risk (congenital heart block, thrombosis, pre-eclampsia). The principle is that active maternal disease is worse for the pregnancy than well-chosen medications, so disease control before conception is paramount. [1]

SAQ 2 — SLE in Pregnancy and Antiphospholipid Syndrome (10 marks)

Prompt: A 31-year-old woman with a 4-year history of SLE (on hydroxychloroquine and mycophenolate mofetil) wishes to conceive. She has had two first-trimester miscarriages. Serology shows a positive lupus anticoagulant, high-titre anticardiolipin IgG (55 GPL units), and positive anti-beta-2 glycoprotein I on two occasions 12 weeks apart. Anti-Ro (SSA) is positive. Her disease has been inactive for 9 months with stable renal function. Discuss your pre-pregnancy assessment, medication adjustments, and the antenatal management plan. [1]

Model Answer

(a) Pre-pregnancy assessment and risk stratification (3 marks): [1]

This patient has SLE with definite antiphospholipid syndrome (secondary APS) — she satisfies the Sydney (2006) criteria with both a clinical event (pregnancy morbidity — recurrent first-trimester loss) and laboratory criteria (lupus anticoagulant, high-titre anticardiolipin, and anti-beta-2 glycoprotein I persistent at least 12 weeks apart) [6]. She is also anti-Ro positive, placing any future fetus at risk of neonatal lupus and congenital heart block.

My pre-pregnancy assessment includes: confirming at least 6 months of disease quiescence (she has 9 months, which is good), documenting stable renal function and inactive urinary sediment, checking anti-dsDNA and complement as a baseline, reviewing her antiphospholipid and anti-Ro status (both abnormal, raising risk), assessing cardiovascular and thrombotic risk, and counselling on the risks — of lupus flare (about 20 to 30 per cent in pregnancy), pre-eclampsia, fetal loss, prematurity, fetal growth restriction, and congenital heart block (1 to 2 per cent risk in an anti-Ro positive mother, rising to 15 to 20 per cent in a subsequent pregnancy after an affected child). [1]

(b) Medication adjustments before conception (3 marks): [1]

• Stop mycophenolate mofetil at least 3 months before conception — it is teratogenic. Switch to azathioprine (2 mg/kg/day), which is safe in pregnancy and lactation.
• Continue hydroxychloroquine throughout — it reduces flare frequency, improves pregnancy outcomes, and reduces the risk of congenital heart block in an anti-Ro positive mother. It is safe in pregnancy and lactation.
• Start low-dose aspirin (75 to 150 mg daily) for APS-related pregnancy prophylaxis — this reduces the risk of pre-eclampsia and recurrent pregnancy loss.
• Plan therapeutic anticoagulation in pregnancy — for APS with prior pregnancy morbidity, the standard is low molecular weight heparin (for example, enoxaparin 40 mg subcutaneously daily, prophylactic dose) combined with low-dose aspirin, commencing once pregnancy is confirmed and continued through the pregnancy and for 6 weeks postpartum. Warfarin is teratogenic (first trimester) and is avoided in pregnancy; it may be used postpartum and is safe in lactation.
• Ensure folic acid 5 mg daily (high dose, given the increased risk) and vitamin D supplementation. [1]

(c) Antenatal management plan (4 marks): [1]

• Shared care with maternal-fetal medicine (obstetric medicine) and rheumatology, with regular review (every 4 weeks in the first and second trimesters, then every 2 weeks).
• Serial fetal echocardiography between 16 and 26 weeks gestation to detect congenital heart block, because she is anti-Ro positive. If first or second degree heart block is detected early, fluorinated steroids (dexamethasone) may be considered, though they are not beneficial once third degree (complete) block is established — and complete block is irreversible, with most affected infants needing a permanent pacemaker. Maternal hydroxychloroquine reduces the risk.
• Monitoring for lupus flare versus pre-eclampsia — a critical and difficult discriminator. Features favouring lupus flare: active urinary sediment, falling complement (C3 and C4), rising anti-dsDNA, extra-renal lupus activity (rash, arthritis), and a stable platelet count. Features favouring pre-eclampsia: raised serum urate, low platelets, abnormal liver function, hyperreflexia, and a placental growth factor pattern. A rising anti-dsDNA with falling complement is the single most discriminating finding pointing to lupus flare. Delivery is the treatment for pre-eclampsia; immunosuppression is the treatment for lupus flare — so the distinction changes management fundamentally.
• Anticoagulation and aspirin continued through pregnancy and for 6 weeks postpartum (then reassessed for lifelong anticoagulation given her thrombotic APS risk).
• Intrapartum and postpartum — plan the mode and timing of delivery with obstetrics (considering the anticoagulation and the APS), ensure postpartum hydroxychloroquine continuation, and provide a clear postpartum flare-monitoring plan. Breastfeeding is compatible with hydroxychloroquine, azathioprine, low-dose steroids, heparin and warfarin. [1]

The key overarching principle is that planned pregnancy during disease quiescence, with pregnancy-compatible medications, anticoagulation for APS, aspirin, and close shared obstetric-rheumatology care, achieves live birth rates of over 85 per cent in modern practice — a dramatic improvement on the historical outlook. [1]